Silodosin
CAS NO: 160970-54-7
STRUCTURE:
APPLICATION : Treatment of benign Prostatic hyperplasia.
Product Information
Silodosin is an alpha-1 adrenergic receptor antagonist used primarily for the treatment of benign prostatic hyperplasia (BPH), a common condition in older men characterized by an enlarged prostate. By selectively blocking the alpha-1A receptors located in the prostate and bladder neck, Silodosin helps relax smooth muscle tissue, thereby improving urine flow and relieving symptoms such as frequent urination, difficulty in starting urination, weak stream, and nocturia. It does not reduce the size of the prostate but significantly improves quality of life by alleviating urinary symptoms.
Silodosin is typically available in 4 mg and 8 mg oral capsule or tablet forms and is usually taken once daily with a meal to enhance absorption. The drug exhibits high protein binding (>97%) and is primarily metabolized in the liver through UGT2B7 and CYP3A4 pathways, with elimination occurring via feces and urine. Common side effects include dizziness, retrograde ejaculation, headache, nasal congestion, and diarrhea. It is contraindicated in individuals with severe liver impairment or known hypersensitivity to the drug.
Caution is advised in patients with renal impairment, and there may be a risk of orthostatic hypotension, particularly during the initial stages of treatment. Silodosin is not indicated for use in women or children. It should be stored in a cool, dry place below 25°C, away from direct sunlight, and is typically supplied in blister packs or bottles.